Tenax Therapeutics Q2 2025 Earnings Report

Tenax Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.50
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Tenax Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tenax Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 13, 2025
• Conference Call Time: 4:00PM ET

Tenax Therapeutics (NASDAQ:TENX) is a clinical‐stage specialty biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary and vascular diseases. Headquartered in Morrisville, North Carolina, Tenax applies proprietary small‐molecule discovery and drug‐delivery technologies to address high‐unmet‐need indications, including acute vaso‐occlusive crises and pulmonary arterial hypertension (PAH).

The company’s lead product candidate is a novel small‐molecule vasodilator currently in Phase 2 clinical trials for the treatment of acute vaso‐occlusive events in patients with sickle cell disease. By targeting the underlying pathophysiology of microvascular blockage, this candidate seeks to improve blood flow and alleviate pain episodes. Concurrently, Tenax is advancing a second program in early‐stage studies for PAH, where initial data have shown encouraging hemodynamic improvements and a favorable safety profile. Formulation strategies under investigation include both oral and inhaled delivery to optimize patient convenience and therapeutic exposure.

Founded in the mid-2010s as a spin-out from a cardiovascular research consortium, Tenax has established a U.S. R&D infrastructure and leverages partnerships with leading academic medical centers and contract research organizations across North America and Europe. This global trial network enables the company to engage diverse patient populations and streamline clinical development timelines, while maintaining rigorous safety and quality standards.

Tenax’s leadership team brings together seasoned professionals with extensive backgrounds in drug discovery, clinical development, regulatory affairs and commercial strategy. The executive management, led by an experienced chief executive officer with more than two decades in life sciences, is supported by a board of directors comprised of industry veterans. This depth of expertise positions Tenax Therapeutics to navigate complex regulatory pathways and advance its pipeline toward delivering new treatment options for serious cardiopulmonary disorders.